MA48780A - Peptides antagonistes de pac1 - Google Patents

Peptides antagonistes de pac1

Info

Publication number
MA48780A
MA48780A MA048780A MA48780A MA48780A MA 48780 A MA48780 A MA 48780A MA 048780 A MA048780 A MA 048780A MA 48780 A MA48780 A MA 48780A MA 48780 A MA48780 A MA 48780A
Authority
MA
Morocco
Prior art keywords
pac1
antagonists
peptides
peptides antagonists
Prior art date
Application number
MA048780A
Other languages
English (en)
Inventor
Irwin Chen
su Chong
Essa Hu Harrington
Fang-Tsao Hong
Jason C Long
Leslie P Miranda
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48780A publication Critical patent/MA48780A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA048780A 2017-06-02 2018-06-01 Peptides antagonistes de pac1 MA48780A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762514440P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
MA48780A true MA48780A (fr) 2020-04-08

Family

ID=62685214

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048780A MA48780A (fr) 2017-06-02 2018-06-01 Peptides antagonistes de pac1

Country Status (11)

Country Link
US (1) US11643440B2 (fr)
EP (1) EP3630147B1 (fr)
JP (1) JP7195281B2 (fr)
AR (1) AR111842A1 (fr)
AU (1) AU2018275270B2 (fr)
CA (1) CA3065115A1 (fr)
ES (1) ES3067856T3 (fr)
MA (1) MA48780A (fr)
TW (1) TW201920235A (fr)
UY (1) UY37753A (fr)
WO (1) WO2018222991A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020264384A1 (fr) 2019-06-28 2020-12-30 Amgen Inc. Protéines de liaison à l'antigène bispécifiques anti-récepteur pac1/anti-récepteur cgrp

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
CA2169298A1 (fr) 1993-09-10 1995-03-16 Martin Chalfie Utilisations d'une proteine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JPH08333392A (ja) * 1995-06-05 1996-12-17 Shiseido Co Ltd 生理活性ポリペプチド類
US6462016B1 (en) * 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US20020182729A1 (en) * 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003092716A2 (fr) 2002-05-03 2003-11-13 Neuronova Ab Role fonctionnel et utilisation therapeutique potentielle de pacap, vip et maxadilan en rapport avec des cellules progenitrices ou souches neuronales chez l'adulte
DE60327366D1 (de) 2002-10-29 2009-06-04 Fundacao Oswaldo Cruz Lutzomyia longipalpis-polypeptide und verwendungsverfahren
CN101125881A (zh) * 2007-07-20 2008-02-20 暨南大学 重组pac1受体结抗剂d(25-44)rmmax及其表达方法与应用
WO2009033489A2 (fr) 2007-09-11 2009-03-19 Glostrup Hospital Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1
WO2009137577A2 (fr) 2008-05-08 2009-11-12 Merial Limited Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
WO2010007175A2 (fr) 2008-07-18 2010-01-21 Galderma Research & Development Modulateurs de voie de signalisation pacap pour traiter des maladies inflammatoires de la peau avec une composante neurogène et plus particulièrement l’acné rosacée et composition contenant ceux-ci
WO2010078469A2 (fr) 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Protéines salivaires de phlébotome en tant que nouveaux inhibiteurs du facteur xa et procédés d'utilisation
JP5447784B2 (ja) 2009-03-12 2014-03-19 国立大学法人 鹿児島大学 マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
CA2797033C (fr) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Polypeptides tres actifs et procedes pour les preparer et les utiliser

Also Published As

Publication number Publication date
JP7195281B2 (ja) 2022-12-23
JP2020522476A (ja) 2020-07-30
EP3630147C0 (fr) 2026-03-25
TW201920235A (zh) 2019-06-01
US20210395313A1 (en) 2021-12-23
WO2018222991A2 (fr) 2018-12-06
AR111842A1 (es) 2019-08-21
EP3630147B1 (fr) 2026-03-25
EP3630147A2 (fr) 2020-04-08
CA3065115A1 (fr) 2018-12-06
AU2018275270B2 (en) 2024-06-06
US11643440B2 (en) 2023-05-09
UY37753A (es) 2018-11-30
AU2018275270A1 (en) 2019-12-12
ES3067856T3 (en) 2026-05-26
WO2018222991A3 (fr) 2019-01-31

Similar Documents

Publication Publication Date Title
IL268920A (en) Peptide vaccines
DK3727461T3 (da) EPHA2-specifikke bicykliske peptidligander
DK3723783T3 (da) Mitokondrie-målrettede peptider
IL268593A (en) Polypeptide variants and uses thereof
PL3649151T3 (pl) Białka rusztowania
EP3362556C0 (fr) Variants polypeptidiques
IL254516A0 (en) Proteins specific for cd137
EP3317294A4 (fr) Peptides stabilisés anti-microbiens
GB201706477D0 (en) Modification of polypeptides
LT3143037T (lt) Alfa4beta7 integrino tioeterio peptidų antagonistaii
DK4089113T3 (da) Polypeptider
IL252812A0 (en) Pirin polypeptide and immune modulation
PT3645518T (pt) Síntese de omecamtiv mecarbil
IL254591A0 (en) Polypeptides
DK3259358T3 (da) Forøget proteinekspression
EP3710462A4 (fr) Analogues de brartémicine
EP3733686A4 (fr) Nouveau peptide
EP3684359C0 (fr) Antagonistes de trpv2
DK3448879T3 (da) Claudin-6 peptider
SE1830065A1 (sv) Spherical beraring
EP3334750A4 (fr) Antagonistes peptidiques du tgf-bêta
DK3310756T3 (da) Thromboxanreceptorantagonister
EP3703716A4 (fr) Expression de neuropeptides
EP3720873C0 (fr) Peptides de type glucagon
EP3704135A4 (fr) Antibiotiques peptidiques